epoxyketone peptideCancer Research Peptides
Carfilzomib (Kyprolis)
A synthetic tetrapeptide epoxyketone proteasome inhibitor. FDA-approved for relapsed/refractory multiple myeloma. Irreversibly inhibits the 20S proteasome chymotrypsin-like activity.
proteasome-inhibitormultiple-myelomacancer-treatmentFDA-approved
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
A synthetic tetrapeptide epoxyketone proteasome inhibitor. FDA-approved for relapsed/refractory multiple myeloma. Irreversibly inhibits the 20S proteasome chymotrypsin-like activity.